Page 26 - Read Online

137. Minchinton AI, Tannock IF. Drug penetration in solid tumours. as a modulator of cellular redox balance. Cancer Res
Nat Rev Cancer 2006;6:583-92. 2008;68:2870-7.
138. Hockel M, Vaupel P. Tumor hypoxia: defi nitions and current 146. Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J,
clinical, biologic, and molecular aspects. J Natl Cancer Inst Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E,
2001;93:266-76. Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K,
139. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer Seo P, Pegram MD, Gluck S. Phase 2 study of neoadjuvant
treatment. Nat Rev Cancer 2004;4:437-47. treatment with NOV-002 in combination with doxorubicin
140. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. and cyclophosphamide followed by docetaxel in patients with
Nat Rev Cancer 2011;11:393-410. HER-2 negative clinical stage II-IIIc breast cancer. Breast
141. Brown JM, Lemmon MJ. Potentiation by the hypoxic Cancer Res Treat 2012;132:215-23.
cytotoxin SR 4233 of cell killing produced by fractionated
irradiation of mouse tumors. Cancer Res 1990;50:7745-9. 147. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T,
142. DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T,
Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y,
Steinhoff MM, Monk BJ. Phase III randomized trial of weekly Baba Y, Ohmura M, Suematsu M, Baba H, Saya H. CD44
cisplatin and irradiation versus cisplatin and tirapazamine variant regulates redox status in cancer cells by stabilizing
and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical the xCT subunit of system xc(-) and thereby promotes tumor
carcinoma limited to the pelvis: a gynecologic oncology group growth. Cancer Cell 2011;19:387-400.
study. J Clin Oncol 2014;32:458-64. 148. Lo M, Ling V, Low C, Wang YZ, Gout PW. Potential use of
143. Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, the anti-infl ammatory drug, sulfasalazine, for targeted therapy
Lorente G, Banica M, Jung D, Wang J, Ma H, Li X, Yang Z, of pancreatic cancer. Curr Oncol 2010;17:9-16.
Hoffman RM, Ammons WS, Hart CP, Matteucci M. Potent and 149. Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR,
highly selective hypoxia-activated achiral phosphoramidate Lam S, Gout PW, Wang YZ. The xc- cystine/glutamate
mustards as anticancer drugs. J Med Chem 2008;51:2412-20. antiporter as a potential therapeutic target for small-cell lung
144. Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, cancer: use of sulfasalazine. Cancer Chemother Pharmacol
Cohn AL, Schelman WR, Stephenson J Jr, Chiorean EG,
Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, 2009;64:463-72.
Eng C, Kroll S, Ryan DP. Randomized phase II trial of 150. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P,
gemcitabine plus TH-302 versus gemcitabine in patients with Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV,
advanced pancreatic cancer. J Clin Oncol 2015;33:1475-81. Cerione RA. Targeting mitochondrial glutaminase
145. Townsend DM, He L, Hutchens S, Garrett TE, Pazoles CJ, activity inhibits oncogenic transformation. Cancer Cell
Tew KD. NOV-002, a glutathione disulfi de mimetic, 2010;18:207-19.

182 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦